RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop

Rapt Therapeutics

07/08/2025 13:11

Overview

RAPT Q2 net loss narrows to $17.6 mln from $27.7 mln last year

Research and development expenses drop; General and administrative expenses rise

Result Drivers

R&D EXPENSES - Decreased to $12.3 mln on reduced spending on zelnecirnon and tivumecirnon, offset by increased costs for RPT904 and early-stage programs

G&A EXPENSES - Increased to $7.2 mln primarily due to higher consulting and facilities costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$17.64 mln
Q2 Basic EPS
-$0.65
Q2 Operating Expenses
$19.54 mln
Q2 Operating Income
-$19.54 mln


Press Release: ID:nGNX3fwM4s

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)